Flornaptitril PET Imaging - Phase 3 (NCT06254469)

Overview

This Phase 3 clinical trial evaluates [F-18]Flornaptitril, a novel PET imaging tracer developed by CereMark Pharma, for the prediction of Alzheimer's disease and differentiation of chronic traumatic encephalopathy (CTE) from AD. The trial represents a significant advancement in tau imaging technology, addressing critical diagnostic challenges in differentiating between various tauopathies that have historically been difficult to distinguish in vivo.

Overview

This Phase 3 clinical trial evaluates [F-18]Flornaptitril, a novel PET imaging tracer developed by CereMark Pharma, for the prediction of Alzheimer's disease and differentiation of chronic traumatic encephalopathy (CTE) from AD. The trial represents a significant advancement in tau imaging technology, addressing critical diagnostic challenges in differentiating between various tauopathies that have historically been difficult to distinguish in vivo.

The development of Flornaptitril stems from the recognition that while existing tau PET tracers like flortaucipir (AV-1451) have revolutionized our ability to visualize tau pathology in Alzheimer's disease, they possess significant limitations that impact their clinical utility, particularly in differentiating AD from other tauopathies and in detecting CTE-specific tau pathology.

Background and Rationale

The Tau Imaging Challenge

Tau protein aggregation is a hallmark of multiple neurodegenerative diseases, collectively known as tauopathies. These include:

• Alzheimer's Disease (AD): Characterized by mixed 3R/4R tau in neurofibrillary tangles
• Progressive Supranuclear Palsy (PSP): Characterized by 4R tau in globose neurofibrillary tangles
• Corticobasal Degeneration (CBD): Characterized by 4R tau in astrocytic plaques and thread-like inclusions
• Chronic Traumatic Encephalopathy (CTE): Characterized by unique 4R tau pathology with perivascular distribution

• Accurate diagnosis and prognosis
• Clinical trial enrichment
• Monitoring disease progression
• Understanding disease mechanisms

Limitations of Current Tau PET Tracers

Current tau PET tracers, particularly flortaucipir (AV-1451), have demonstrated excellent binding to paired helical filament (PHF) tau in Alzheimer's disease. However, several limitations have emerged[@schöll2020]:

Specificity Limitations

• Limited specificity for 4R-tauopathies (PSP, CBD)
• Off-target binding in the basal ganglia and other regions
• Inability to reliably distinguish CTE tau pathology from AD tau
• Variable binding to different tau conformations

• Signal contamination from off-target binding
• Difficulties in quantifying true tau burden
• Limited sensitivity for early-stage pathology
• Challenges in distinguishing AD from other neurodegenerative conditions

• Difficulty in differential diagnosis
• Limited utility in monitoring disease progression
• Challenges in clinical trial endpoints
• Inability to detect CTE-specific pathology

Flornaptitril Differentiation

[F-18]Flornaptitril represents a next-generation tau PET tracer designed to address these limitations. The tracer is specifically engineered to[@floirnaptitril2023]:

• Bind selectively to different tau conformations: Recognition of structural differences between 3R/4R, 4R-only, and CTE-specific tau aggregates
• Differentiate CTE pathology from AD pathology: Unique binding properties that distinguish CTE-specific tau conformations
• Provide better quantification of tau burden: Improved signal-to-background ratios
• Support differential diagnosis in ambiguous cases: Enhanced ability to distinguish between tauopathies

Novel Mechanism

Flornaptitril is a tau-selective PET tracer that recognizes conformational differences between various tau aggregate types:

| Tau Type | Characteristic | Flornaptitril Binding |
|----------|----------------|----------------------|
| 3R/4R tau (AD) | Paired helical filaments | High affinity |
| 4R tau (PSP, CBD) | Straight filaments | Moderate-high affinity |
| CTE-specific tau | Perivascular, dot-like | High, selective |

This selective binding profile enables visualization of disease-specific tau pathology patterns that were previously undetectable with conventional tau PET tracers.

Trial Details

Study Design

| Parameter | Value |
|-----------|-------|
| Trial ID | NCT06254469 |
| Phase | Phase 3 |
| Status | Recruiting |
| Participants | 230 |
| Sponsor | CereMark Pharma |
| Intervention | [F-18]Flornaptitril PET imaging |
| Indication | Alzheimer's disease prediction, CTE differentiation |
| Duration | 24 months |
| Design | Multi-center, single-arm, open-label |

Treatment Regimen

The trial protocol includes:

• Baseline [F-18]Flornaptitril injection: Intravenous administration of 185-370 MBq
• PET scanning: Dynamic PET acquisition from 30-90 minutes post-injection
• Cognitive assessments: Comprehensive neuropsychological testing at baseline and follow-up
• Follow-up imaging: Repeat PET at 12 and 24 months
• Safety monitoring: Continuous assessment of adverse events

Imaging Protocol

Standardized imaging parameters ensure consistency across sites:

• Scanner requirements: PET/CT with resolution ≤ 4mm
• Acquisition protocol: 4 x 15-minute frames from 30-90 min post-injection
• Reconstruction: OSEM with attenuation correction
• Quantification: Standardized uptake value ratio (SUVR) to cerebellum

Inclusion Criteria

General Criteria

• Age 50-85 years
• Ability to provide informed consent
• Willingness to undergo PET imaging

• Clinical diagnosis of mild cognitive impairment (MCI) due to AD or mild-moderate AD
• MMSE score 16-26
• Amyloid PET positive (if available)
• Agreement to undergo all study procedures

• History of repetitive head trauma (contact sports, military, etc.)
• Clinical suspicion of CTE
• Cognitive and/or behavioral symptoms consistent with CTE
• Exclusion of other neurodegenerative conditions

Exclusion Criteria

• Contraindication to PET imaging
• Significant medical conditions affecting brain function
• Current participation in other clinical trials
• Pregnancy or breastfeeding
• Inability to remain still for PET scanning

Outcome Measures

Primary Endpoints

Tau Binding Quantification

• Standardized uptake value ratio (SUVR) in target brain regions
• Regional distribution pattern analysis
• Comparison with histopathological correlates (in subset)

• Sensitivity and specificity for AD vs. CTE differentiation
• Comparison with clinical diagnosis
• Receiver operating characteristic (ROC) analysis

Secondary Endpoints

Biomarker Correlations

• Correlation with CSF tau biomarkers (total tau, phosphorylated tau)
• Correlation with amyloid PET (for AD cohort)
• Correlation with neurofilament light chain (NfL)

• Correlation with cognitive measures (MMSE, ADAS-Cog, MoCA)
• Correlation with functional measures (ADL, CDR)
• Longitudinal cognitive trajectories

• Incidence of adverse events
• Vital sign changes
• Laboratory abnormalities
• Radiation dosimetry

Exploratory Endpoints

• Comparison with other tau PET tracers (in subset)
• Machine learning classification algorithms
• Genetic correlations (APOE status)
• Neuropathological validation (when available)

Imaging Targets and Patterns

Regional Distribution Patterns

The imaging analysis focuses on specific brain regions with characteristic patterns for each tauopathy:

| Brain Region | AD Pattern | PSP Pattern | CTE Pattern |
|--------------|------------|-------------|-------------|
| Hippocampus | High (early) | Moderate | Variable |
| Entorhinal cortex | High (early) | Moderate | Variable |
| Temporal neocortex | High (temporal > frontal) | Moderate | Variable |
| Frontal cortex | Moderate | Moderate | High (perivascular) |
| Parietal cortex | High | Low | Variable |
| Occipital cortex | Moderate | Low | Variable |
| Basal ganglia | Low | High | Variable |
| Brainstem | Low | High | Variable |

Quantitative Analysis

Standardized uptake value ratios are calculated for key regions:

• Composite cortical SUVR: Mean of frontal, temporal, parietal, occipital cortex
• Hippocampal SUVR: Normalized to cerebellum
• Entorhinal SUVR: For early detection
• Brainstem SUVR: For PSP differentiation

Clinical Significance

Diagnostic Utility

The Flornaptitril PET imaging offers several clinical advantages:

Differential Diagnosis

• Improved distinction between AD and 4R-tauopathies
• Detection of CTE-specific tau pathology in vivo
• Earlier detection of tau pathology in MCI

• Correlation with disease severity
• Prediction of cognitive decline
• Stratification for clinical trials

• Assessment of disease modification
• Target engagement verification
• Biomarker-driven patient selection

Impact on Clinical Practice

The availability of Flornaptitril PET would significantly impact:

Clinical Diagnosis

• More accurate diagnosis in early disease stages
• Better differentiation of atypical presentations
• Improved confidence in challenging cases

• Earlier intervention opportunities
• Better treatment planning
• More accurate prognosis

• Improved clinical trial design
• Better patient stratification
• Enhanced biomarker endpoints

Comparison with Other Tracers

| Feature | Flornaptitril | Flortaucipir (AV-1451) | Others |
|---------|---------------|------------------------|--------|
| AD detection | Excellent | Excellent | Good |
| 4R-tau selectivity | High | Low | Moderate |
| CTE detection | Yes | No | Limited |
| Off-target binding | Low | Moderate | Variable |
| Quantification | Improved | Standard | Standard |

Related Conditions

Alzheimer's Disease

Flornaptitril PET provides detailed visualization of tau pathology in AD, enabling:

• Early detection in MCI stages
• Correlation with amyloid burden
• Tracking of disease progression
• Differentiation from other dementias

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Tau Pathology in AD](/mechanisms/tau-pathology)
• [Amyloid PET Imaging](/biomarkers/amyloid-pet)

Chronic Traumatic Encephalopathy

CTE represents a unique challenge that Flornaptitril specifically addresses:

• Detection of CTE-specific tau pathology
• Differentiation from AD in athletes
• Correlation with exposure history
• Support for clinical diagnosis

• [Chronic Traumatic Encephalopathy](/diseases/chronic-traumatic-encephalopathy)
• [Tauopathies Overview](/mechanisms/tauopathy)
• [Traumatic Brain Injury](/diseases/traumatic-brain-injury)

Progressive Supranuclear Palsy

The 4R-tau selectivity of Flornaptitril enables better visualization of PSP pathology:

• Detection of brainstem involvement
• Correlation with clinical subtypes
• Differentiation from other parkinsonisms

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [4R-Tauopathies](/mechanisms/4r-tauopathies)

Company Background

CereMark Pharma is a pharmaceutical company focused on developing novel molecular imaging agents for neurological disorders. Their pipeline includes PET tracers for:

• Tau protein (Flornaptitril)
• Amyloid-beta (in development)
• Alpha-synuclein (preclinical)
• Neuroinflammation (TSPO, in development)

Safety Considerations

Radiation Safety

• Effective dose: Approximately 5-7 mSv per scan
• Comparable to routine CT procedures
• Strict adherence to ALARA principles

Adverse Event Profile

Based on Phase 1/2 data:

• Generally well-tolerated
• No significant injection-related reactions
• No dose-limiting toxicities observed

Contraindications

• Pregnancy
• Severe renal impairment (delayed clearance)
• Active infection or inflammation

Future Directions

Development Roadmap

• Phase 3 completion: Expected by 2027
• Regulatory submission: Planned for 2028
• Commercial availability: Projected 2029

Potential Applications

Beyond the current indications, Flornaptitril may have utility in:

• Monitoring treatment response in clinical trials
• Stratifying patients for anti-tau therapies
• Understanding tau spread in aging and disease
• Research applications in tau biology

Comparative Effectiveness

Head-to-head studies comparing Flornaptitril with:

• Flortaucipir in AD patients
• Other tau PET tracers
• CSF biomarkers
• Neuropathological correlates

Cross-Links to Related Pages

Tau Imaging and Biomarkers

• [Tau PET Imaging](/biomarkers/tau-pet)
• [CSF Tau Biomarkers](/biomarkers/csf-tau)
• [Amyloid PET Imaging](/biomarkers/amyloid-pet)
• [Neuroimaging in AD](/mechanisms/neuroimaging-alzheimers)

Tauopathies

• [Tauopathies Overview](/mechanisms/tauopathy)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
• [Chronic Traumatic Encephalopathy](/diseases/chronic-traumatic-encephalopathy)

Clinical Trial Resources

• [Clinical Trials Overview](/clinical-trials/dashboard)
• [Active Alzheimer's Trials](/clinical-trials/alzheimers-disease)
• [Dementia Imaging Trials](/clinical-trials/drug-pipeline)

Research and Treatment

• [Anti-Tau Therapies](/therapeutics/anti-tau-therapies)
• [Tau Immunotherapy](/mechanisms/tau-immunotherapy-mechanisms)
• [Tau Kinase Inhibitors](/therapeutics/tau-kinase-inhibitors)

Conclusion

The Flornaptitril Phase 3 trial represents a significant step forward in tau imaging for neurodegenerative diseases. By specifically addressing the limitations of current tau PET tracers, particularly in differentiating CTE from AD and improving visualization of 4R-tauopathies, this trial has the potential to transform diagnostic capabilities for these conditions.

The successful development of Flornaptitril would provide clinicians with a powerful tool for:

• More accurate differential diagnosis
• Better understanding of disease mechanisms
• Improved clinical trial design
• Enhanced patient care